Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2784588 | 1.00 | SLC7A5 (0.38) | SLC7A5TDP1GRIK1GRIK2GRM1 | |
| SCHEMBL5293647 | 0.80 | GRIK1 (0.42) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL4632171 | 0.80 | GRIK1 (0.42) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL18277715 | 0.80 | GRIK1 (0.42) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL9156122 | 0.74 | TDP1 (0.45) | SLC7A5TDP1GRIK1GRIK2GRM1 | |
| SCHEMBL7997976 | 0.73 | — | — | |
| SCHEMBL3417424 | 0.72 | TDP1 (0.36) | SLC7A5TDP1GRIK1GRIK2GRM1 | |
| SCHEMBL7039023 | 0.72 | GRIK1 (0.37) | SLC7A5GRIK1GRIK2GRM1GRM2 | |
| SCHEMBL209221 | 0.71 | — | — | |
| SCHEMBL88708 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7778779-B2 | Method of identifying a chemical entity which is a hydroxylase modulator | ISIS INNOVATION LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| EP-2156830-A1 | Modulators of asparaginyl hydoxylase activity of FIH | ISIS INNOVATION LIMITED (GB) | 2010-02-24 | — | — | EP | disclosed |
| EP-1554394-B1 | Screening methods using a structural model of FIH | ISIS INNOVATION (GB) | 2009-12-16 | — | — | EP | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-20070048728-A1 | Hydroxylases and modulators thereof | ISIS INNOVATION LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
| EP-1554394-A2 | ASPARAGINYL HYDROXYLASES AND MODULATORS THEREOF | ISIS INNOVATION LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004035812-A2 | ASPARAGINYL HYDROXYLASES AND MODULATORS THEREOF | ISIS INNOVATION LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070048728-A1 | Hydroxylases and modulators thereof | EGLN3, HIF1AN, EGLN2 | SLC7A5 3185/4885TDP1 3071/4885GRIK1 4249/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | SLC7A5 3712/4885TDP1 3112/4885GRIK1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.